Rinase

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rinase

Quick Facts

Property Description
Active ingredient Ipratropium Bromide
Form Metered-dose nasal spray (aqueous solution)
Pharmacological class Anticholinergic agent / Antimuscarinic agent
Common purpose Control of excessive watery nasal discharge (hypersecretion)
Origin Synthetic (atropine derivative)

What Type of Medicine is Rinase?

Rinase is a proprietary pharmaceutical preparation whose sole active ingredient is Ipratropium Bromide, classified as a specialized anticholinergic agent used for targeted local effect. The medicine is a synthetic compound derived from the alkaloid atropine, chemically structured as a quaternary ammonium compound. This chemical structure limits the substance from being readily absorbed into the general circulation, ensuring its action remains localized primarily to the intranasal application site, a property associated with a reduced potential for systemic effects. The preparation is typically categorized as a prescription drug (Rx), distinguishing it from many over-the-counter nasal relief products.


Composition and Physical Form

The medication is formulated as an aqueous solution dispensed via a metered-dose nasal spray, which is its defined dosage form. As a single-entity product, it contains only the active ingredient and a water-based vehicle with essential excipients. This formulation and delivery method are designed for effective deposition on the nasal mucosa. This topical delivery system is utilized to maximize the concentration of the drug on the nasal mucosa, the direct target area for the medicine’s effect, allowing the drug to act locally without the higher systemic exposure typically associated with oral medications.


General Purpose and Mechanism Principle

The general purpose of Rinase is the specific management and control of excessive watery nasal discharge, known as hypersecretion. This action is achieved through the mechanism principle of muscarinic receptor antagonism, where Ipratropium Bromide blocks the receptors that regulate glandular secretions. This targeted action helps reduce the symptom of a dripping nose, such as that experienced during seasonal or non-allergic rhinitis. By inhibiting the nervous system’s signaling for fluid release (cholinergic stimulation), the preparation provides relief by directly controlling the mechanism of fluid production.

What side effects are possible with Rinase?

Possible Side Effects and Safety Information

The safety profile of Rinase is primarily characterized by the risk of respiratory sensitization upon inhalation, as documented in regulatory hazard classifications (e.g., GHS/CLP). This designation indicates that the substance may lead to hypersensitivity of the airways, often after repeated exposure.

Documented Adverse Reactions

The most clinically significant adverse reactions officially noted are those related to the respiratory and immune systems:

  • Respiratory/Allergic Phenomena: May cause allergy or asthma symptoms or breathing difficulties if inhaled. The common acute or delayed symptoms of exposure include allergic reactions, cough, and dyspnoea (shortness of breath).

Because Rinase is classified as a respiratory sensitizer, the immune-mediated reaction can be triggered even by low concentrations once a person has become sensitized.

Safety and Exposure Restrictions

Official documents define specific limitations on use and handling to mitigate the primary inhalation hazard:

  • Inhalation Avoidance: It is mandated to avoid breathing the mist, vapors, or spray generated by the product, particularly during handling where dust formation may occur.
  • Medical Follow-up: If an individual experiences respiratory symptoms following exposure, such as asthma-like reactions or breathing difficulties, immediate medical attention is necessary, as indicated by regulatory response statements.

This safety information is based on governmental regulatory frameworks that classify chemical hazards, structuring the understanding of risk around the substance’s potential for respiratory system sensitization.

Overdose and Emergency Response

Overdose and When to Seek Help

The official prescribing information indicates that acute systemic overdosage is unlikely following intranasal administration of Rinase. This outcome is consistent with the drug's classification as a quaternary ammonium compound, which results in minimal systemic absorption from the nasal mucosa. Regulatory studies examining high doses, equivalent to ingesting several units of the nasal spray, demonstrated no noted change in heart rate or blood pressure. Should significant systemic exposure occur, the anticipated clinical presentation would be related to the drug's pharmacology, manifesting as exaggerated peripheral anticholinergic effects.

Required Emergency Actions

  • Individuals who suspect a clear overdosage must contact a poison control center or emergency room at once.
  • The manifestation of severe local effects, such as eye pain or blurred vision following ocular exposure, also requires contact with a physician.
  • Management for a potential overdose is focused on providing symptomatic and supportive treatment because no specific antidote is documented in the official regulatory labels.
  • The overdose risk profile has not been formally studied in patients with hepatic or renal insufficiency.

Therapeutic Uses of Rinase

What Rinase Treats: Main Uses and Benefits

The medication is commonly used for the symptomatic relief of rhinorrhea—the medical term for symptoms related to heightened physiological activity, specifically excessive watery nasal secretions. This medication is applied across domains where additional symptomatic support is needed in situations involving certain distressing symptoms.

The medication is commonly used across conditions characterized by periods of heightened symptoms, specifically applied for the excessive watery discharge observed in seasonal and perennial allergic rhinitis (hay fever), non-allergic rhinitis, and the rhinorrhea associated with the common cold. It is also relevant for easing symptoms related to chronic or situation-specific fluid problems, such as gustatory rhinitis (runny nose triggered by eating).

This treatment is relevant in clinical settings that involve acute or unstable symptom patterns. It provides support that helps ease the overall symptom burden during episodes of heightened discomfort and assists with maintaining functional stability when symptoms interfere with routine activities.

Quick Fact: Relief for Watery Discharge
Primary Target Symptom Excessive watery nasal discharge (Rhinorrhea)
Targeted Conditions Seasonal/Perennial Allergic Rhinitis, Non-Allergic Rhinitis, Common Cold
Main Patient Benefit Supports day-to-day comfort and stability during symptomatic periods

Eligibility and Restrictions for Use

Who Can and Cannot Use Rinase?

Eligibility to use Rinase (Ipratropium Bromide Nasal Spray) is strictly defined by government regulatory documents, focusing on age, allergies, and pre-existing conditions.


Contraindications and Age Eligibility

Classification Population Details
Absolute Contraindication Patients with a known allergy or hypersensitivity to Ipratropium Bromide or to atropine derivatives (due to the drug's origin).
Minimum Age for Use 5 years and older (for 0.06% strength); 6 years and older (for 0.03% strength).
Use Not Established Children below the approved minimum age thresholds.

Conditions Requiring Caution

Due to its anticholinergic properties, Rinase must be used with caution in patients with specific conditions, as documented in official labeling:

  • Narrow-Angle Glaucoma
  • Prostatic Hyperplasia (enlarged prostate)
  • Bladder Neck Obstruction
  • Hepatic or Renal Impairment (Use advised with caution as pharmacokinetics have not been studied in these groups).

Pregnancy and Lactation Status

Use during pregnancy is advised only if clearly needed. Use in nursing mothers requires caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Ipratropium Bromide nasal spray (Rinase) indicates that the medicine's interaction profile is limited, primarily due to its minimal systemic absorption following intranasal application. Interaction warnings focus mainly on pharmacodynamic additive effects and hypersensitivity risks, rather than systemic pharmacokinetic changes.

Pharmacodynamic and Contraindicated Combinations

Co-administration with other anticholinergic medications may result in an additive pharmacodynamic effect, which is an officially documented concern. Caution is noted when patients are receiving an anticholinergic by another route, such as orally or via inhalation. Additionally, the use of Rinase is contraindicated in individuals with a history of hypersensitivity to atropine or its derivatives, reflecting the drug's chemical classification as an atropine derivative.

Pharmacokinetic and General Interaction Status

Regulatory documents explicitly state that no specific pharmacokinetic studies were conducted to evaluate potential systemic drug–drug interactions, meaning no interactions involving CYP enzymes, drug transporters, or other exposure-modifying substances are formally documented in the label. Consequently, there are no official restrictions regarding co-administration with food, alcohol, or herbal products.

Population-Specific Notes

The pharmacokinetics of Ipratropium Bromide have not been studied in patient populations with hepatic or renal insufficiency. Official caution is noted regarding use in these patient groups.

Mechanism of Action

Blocking the Parasympathetic Secretion Signal

The active ingredient, Ipratropium Bromide, functions as a competitive antagonist by binding to the muscarinic acetylcholine receptors (M-receptors, primarily M3 subtype) on the nasal glands. This action physically prevents the binding of the natural neurotransmitter, acetylcholine, and the subsequent initiation of the parasympathetic secretory reflex in the serous and seromucous glands.


Anti-Secretory Cascade and Localized Effect

The receptor blockade immediately aborts the internal molecular sequence—specifically the cGMP second messenger cascade—which mediates fluid release from the gland cells. This interruption results in the inhibition of glandular output, which represents the physiological consequence of the anti-secretory mechanism. Because the drug is formulated as a quaternary ammonium compound, its effect is highly localized to the nasal mucosa, characterized by minimal systemic exposure.


Mechanistic Boundaries and Specificity

The mechanism of action is strictly anti-secretory, modulating nerve signals that regulate fluid volume. This mechanism does not influence the physiological pathways governing tissue swelling, inflammation, or irritant reflexes. Therefore, the drug’s physiological action is constrained to regulating glandular secretion and does not affect the distinct mechanisms underlying nasal congestion or sneezing.

Dosage and Administration Information

How to Use Rinase

Rinase (Ipratropium Bromide Nasal Spray) is administered strictly through the topical intranasal route as a metered-dose aqueous solution. The correct use of the medicine is determined by its specific concentration and the condition being managed.

Official Dosing Regimens

Dosages are defined by the number of sprays per nostril and vary based on the concentration of the product:

Indication/Concentration Dose per Application (per nostril) Frequency Max Daily Dose (per nostril)
0.03% (Allergic/Non-allergic Rhinitis) 2 sprays (42 mcg) Three times daily (t.i.d.) 6 sprays (252 mcg)
0.06% (Common Cold Rhinorrhea) 2 sprays (84 mcg) Three to four times daily (t.i.d. to q.i.d.) 8 sprays (336 mcg)

Administration Requirements and Duration

Prior to initial use, the nasal spray pump must be primed by releasing several test sprays (typically seven) until a fine mist is produced; repriming is also required if the device is unused for more than 24 hours. For correct application, the user must point the tip toward the back and outer side of the nose while sniffing deeply to ensure proper drug distribution.

The duration of use is constrained by the condition. For rhinorrhea associated with the common cold (0.06% concentration), use is limited to a maximum of four days. The medication is approved for pediatric patients aged 5 years and older for the 0.06% strength and 6 years and older for the 0.03% strength, using the same adult dosing schedules. If a dose is missed, the standard procedure is to simply take the next dose at the regularly scheduled time.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Rinase


Evidence for Use in Seasonal Allergic Rhinitis

Research exploring the use of the medicine for the excessive watery nasal discharge symptom, such as seasonal allergic rhinitis, primarily consists of short-term, controlled clinical trials. These studies were used in research exploring how symptoms change over time, often comparing the active medicine to a placebo (vehicle spray). Researchers monitored how patients reported their perceived discomfort using symptom scales and also utilized objective measures like weighing nasal secretions. Studies were conducted in adults and children to evaluate outcomes related to watery nasal discharge.

Studies conducted during periods of increased symptom activity reported measurements of changes in the intensity and duration of watery discharge when comparing the groups. The primary outcomes studied were relevant in trials assessing short-term or episodic symptom patterns, as the research primarily centered on this single symptom. However, evidence describing how symptoms are measured in relation to other associated complaints, such as nasal congestion or sneezing, often indicated mixed or limited reported outcomes in those areas.


Evidence for Use in Perennial Allergic and Non-Allergic Rhinitis

Rinase was studied for conditions involving periods of heightened symptoms associated with chronic rhinitis, including both perennial allergic rhinitis (PAR) and non-allergic perennial rhinitis (NAPR). For both conditions, studies explored how symptoms evolved in the observed populations over intermediate follow-up periods, typically lasting up to two or three months. These studies primarily focused on outcomes related to physical discomfort from the persistent watery discharge. Research examined the use of the medicine for the chronic, watery nasal discharge symptom.

For perennial rhinitis, findings describe patterns observed in the studies regarding the symptom of rhinorrhea. The non-allergic rhinitis population itself is heterogeneous, meaning the evidence quality varies across studies when trying to apply findings to specific subtypes. Long-term effects are not fully established under controlled conditions, particularly for the non-allergic group.


What is Still Uncertain About the Research Base

The research base, while contributing to the understanding of symptom patterns, still has recognized limitations. The evidence is limited for a broad range of patient populations, and research primarily focuses on the specific symptom of watery nasal discharge, which is only one component of rhinitis conditions. Comparative evidence against other medications is lacking. Certainty remains low regarding the effect of the medicine on associated symptoms like nasal congestion, as findings were mixed. Furthermore, there is limited information for long-term outcomes, as follow-up durations were restricted in many pivotal studies.

Key Studies & References

  1. Efficacy and safety of ipratropium bromide nasal spray in non-allergic perennial rhinitis: A systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Rinase (FAQ)

Q: How quickly does Rinase usually start working?

A: Official clinical trial information indicates that the onset of action—the time the medicine begins to work—is generally observed within 15 minutes of administration for perennial rhinitis. This observed onset is consistent with the drug's localized topical application in the nose. However, the time until full relief is achieved may vary.

Q: Is it normal to feel [vague side effect like dizziness/fatigue] when starting Rinase?

A: According to regulatory documents, reported side effects include headache and dizziness. These effects are listed in the adverse reactions section of the official product information. If these or other symptoms become bothersome, reviewing the situation with a healthcare provider is generally recommended.

Q: Why do some patients stop taking Rinase?

A: Official studies have indicated that some patients discontinue use due to lower respiratory adverse reactions, such as shortness of breath (dyspnea) or inflammation of the airways (bronchitis). Discontinuation has also been reported due to common localized side effects like headache or nasal irritation.

Q: Can Rinase affect my ability to drive or operate machinery?

A: The official product information notes that Rinase may cause certain effects such as dizziness, blurred vision, or an accommodation disorder (difficulty focusing). Therefore, engaging in activities that require mental alertness and visual acuity, such as driving or operating machinery, may require caution.

Q: What is the typical timeframe to see the full effect of Rinase?

A: While some patients may notice an initial benefit soon after starting, official patient information suggests that for others, it can take 1 to 2 weeks of regular use before the medicine provides its full benefit. This timeframe reflects the period observed in patient information before the medicine may provide full relief.

Q: Are headaches a common side effect of Rinase?

A: Headaches are listed in official product information as one of the most frequently reported adverse events. Clinical trials indicate that the incidence of headache ranges between 4% and nearly 10%, depending on the specific concentration of the product used.

Q: What should I do if the side effects of Rinase become bothersome?

A: Official guidance indicates that persistent or bothersome local symptoms, such as excessive dryness of the nose or occasional nasal bleeding, may warrant consulting the prescribing healthcare provider. This ensures any necessary clinical adjustments can be reviewed.

Q: What is the longest time someone typically needs to take Rinase?

A: Regulatory documents limit the use of the 0.06% strength for the common cold to a maximum of four days. For seasonal allergic rhinitis, the safety and effectiveness for use beyond three weeks has not been definitively established in official research.

Q: Are the side effects of Rinase generally mild?

A: Official information indicates that the most commonly observed side effects are localized and generally mild, such as nasal dryness or irritation. However, the safety profile includes the rare potential for serious, immediate hypersensitivity reactions, which involve symptoms like rash, swelling, or difficulty breathing.

Q: Can I take Rinase if I have [Common Chronic Condition, e.g., high blood pressure]?

A: Clinical trials specifically examining the drug’s effects on heart rate and blood pressure found no significant impact. Official documentation advises that individuals with any chronic medical condition, including those not specifically listed as cautions, reviewing their full medical history with a healthcare provider before starting Rinase is generally advisable.

Q: Is Rinase a long-term medication?

A: Official prescribing information indicates that for the common cold, use is restricted to 4 days. Furthermore, the safety and effectiveness for use beyond three weeks has not been definitively established for seasonal allergic rhinitis, suggesting a limitation on current long-term prescribing data.

Q: Can women who are planning to conceive take Rinase?

A: Regulatory information based on animal studies indicates no impairment of fertility at exposure levels comparable to typical human use. However, explicit human reproductive risk information for the pre-conception period is not included in the official product labeling.

Q: Are there any specific lifestyle restrictions while on Rinase?

A: Patients are officially advised to avoid spraying the medicine in their eyes or surrounding areas, as this can cause irritation or vision changes. Furthermore, caution may be advisable for activities that require balance or visual acuity, such as driving, due to the potential for temporary side effects like dizziness.

Q: Is Rinase considered safe for long-term use?

A: Official documents indicate that safety and effectiveness for use beyond 3 weeks has not been established for seasonal rhinitis, and is limited to 4 days for the common cold. Research on long-term outcomes for perennial rhinitis remains limited, reflecting an absence of definitive data on extended-duration use.

Q: What are the signs of an allergic reaction to Rinase?

A: Signs of an immediate allergic reaction, or hypersensitivity, may include symptoms such as hives (urticaria), a rash, or swelling of the face, lips, or tongue (angioedema). More severe reactions may involve trouble breathing due to tightening of the airways (bronchospasm).

Q: Is Rinase used for any condition besides the main one it treats?

A: Official regulatory documents indicate that Rinase is approved for the symptomatic relief of excessive watery nasal discharge (rhinorrhea). This includes symptoms associated with the common cold, seasonal allergic rhinitis, and perennial rhinitis (both allergic and non-allergic types).

Q: What is the 'mechanism of action' of Rinase in simple terms?

A: Rinase is an anticholinergic agent that acts locally within the nasal passages. Its mechanism involves blocking the specific nerve signals that cause the nasal glands to produce excess secretions. This targeted action directly helps to reduce the symptom of watery nasal discharge.

Q: What are contraindications for Rinase in simple language?

A: Official prescribing documents state that the medicine is contraindicated, meaning it should not be used, if a patient has a known allergy or severe hypersensitivity to ipratropium bromide, atropine, or any medicine that is a derivative of atropine.

How should Rinase be stored and disposed of?

Rinase (ipratropium bromide) nasal spray must be stored according to specific conditions mandated by regulatory authorities to maintain its stability and effectiveness.

Storage Requirements

Condition Regulatory Mandate
Temperature Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F), with permitted excursions up to 30 C
Protection Do not freeze and protect the product from light and excessive moisture
Container Keep in the original container and ensure the bottle is tightly closed
Child Safety Keep out of reach of children

Disposal Instructions

Mandate Instruction
Discard Timing Throw away the bottle after the prescribed number of sprays has been used, or after a specific in-use period (e.g., twelve months) following the first opening, whichever comes first
Waste Handling Dispose of expired or unused medication as instructed by a healthcare professional or pharmacist, following local regulations for pharmaceutical waste. Do not dispose of the product in wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rinase found in:

A-Z Index: